Oscar Health (OSCR) reported Thursday a Q3 loss of $0.22 per diluted share, narrowing from a loss of $0.29 a year earlier.
Analysts polled by Capital IQ expected a GAAP loss of $0.20.
Revenue for the quarter ended Sept. 30 was $2.42 billion, up from $1.44 billion a year earlier.
Analysts surveyed by Capital IQ expected $2.35 billion.
The company said it expects 2024 revenue of $9.2 billion to $9.3 billion, compared with the previous forecast of $9 billion to $9.1 billion. Analysts polled by Capital IQ expect $9.05 billion.
Price: 16.85, Change: -0.19, Percent Change: -1.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.